NIH 'blueprint' network aims to speed Sage's Fragile X R&D
This article was originally published in Scrip
Executive Summary
In winning a collaborative grant from the National Institutes of Health (NIH), Cambridge, Massachusetts-based biotech Sage Therapeutics is gaining more than funds potentially worth up to $10m, but also the type of support and resources generally only big pharmas have at their disposal.